| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Amino-PEG4-CH2CO2H does not have a specific biological target, as it is a chemical linker. Its function is to serve as a covalent connector between molecular components in the synthesis of bioconjugates, such as PROTACs and ADCs. The primary amine group is a target for conjugation with carboxylic acids or activated esters (e.g., NHS esters) to form stable amide bonds. The carboxylic acid group is a target for conjugation with primary amines to form amide bonds. The hydrophilic PEG4 spacer enhances solubility and reduces steric hindrance between the conjugated components.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [1]. ADC is made up of antibodies that are connected to ADC cytotoxins by an ADC linker [2].
As a chemical linker, Amino-PEG4-CH2CO2H does not possess any direct in vitro biological activity. Its function is to enable the synthesis of bioactive conjugates. The in vitro activity of this linker is assessed indirectly through the characterization of the final conjugates it helps to create. For instance, when used to synthesize a PROTAC, the biological activity is measured by the extent of target protein degradation in cell-based assays. The efficiency of the conjugation reactions (amine coupling and carboxylic acid activation) are the primary measures of this linker's performance in vitro. |
| ln Vivo |
As a chemical linker, Amino-PEG4-CH2CO2H is not intended for in vivo use as a standalone compound. Its relevance in vivo is as a component of larger conjugates, such as PROTACs or ADCs. In these contexts, the hydrophilic PEG4 spacer contributes to the overall pharmacokinetic profile of the conjugate by improving solubility and reducing aggregation. However, the specific in vivo activity—such as target protein degradation or tumor regression—is determined by the conjugate's warhead and targeting ligand, not the linker itself. The linker's role is to stably connect the functional components.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Amino-PEG4-CH2CO2H, as it is a chemical reagent. Its characterization is performed using analytical chemistry techniques such as NMR, HPLC, and MS to verify its structure and purity. The functionality of the amine and carboxylic acid groups can be confirmed by reacting the compound with model coupling partners and monitoring the formation of amide bonds by HPLC or LC-MS. These are quality control steps, not biological assays.
|
| Cell Assay |
There are no standard in vitro cell-based assays for Amino-PEG4-CH2CO2H itself, as it is not a bioactive molecule. Its use in cell biology is indirect, as a reagent for constructing bioconjugates. For example, when used to create a PROTAC, the PROTAC's ability to degrade a target protein would be evaluated in cell-based assays. The linker's role is to ensure the PROTAC is functional and stable. However, there is no direct assay for the linker in cells. Its purity and reactivity are confirmed through chemical assays before use in any biological experiment.
|
| Animal Protocol |
Amino-PEG4-CH2CO2H is not used in in vivo animal experiments as a standalone compound. It is a synthetic building block for creating bioconjugates such as PROTACs or ADCs. Animal studies would be conducted on the final, larger conjugates that incorporate this linker. In such studies, the linker's contribution to the overall pharmacokinetic and pharmacodynamic profile of the conjugate might be assessed by comparing it to conjugates made with different linkers. However, there is no standard animal protocol for the linker itself. Its use is limited to the research and development phase for synthesizing test articles.
|
| ADME/Pharmacokinetics |
Amino-PEG4-CH2CO2H has a molecular formula of C10H21NO6. It has a CAS number of 195071-49-9. It is a solid compound with a purity of 95%. It is soluble in water. For storage, it is recommended to keep the compound at -20°C in a dry, dark environment. Detailed pharmacokinetic properties are not relevant as the compound is a linker, not a therapeutic agent. As a research chemical, its stability is maintained by proper storage as a dry powder.
|
| Toxicity/Toxicokinetics |
Amino-PEG4-CH2CO2H is considered to have low toxicity, consistent with other PEG-based linkers. PEG polymers are widely regarded as biocompatible, non-toxic, and non-immunogenic. The compound is classified as a research reagent, and standard laboratory safety precautions should be followed when handling it. Its toxicity profile has not been extensively studied, but due to its intended use and chemical class, it is not expected to be acutely toxic. As with all chemicals, it should be handled with appropriate personal protective equipment in a well-ventilated area.
|
| Additional Infomation |
Amino-PEG4-CH2CO2H is a research-use-only reagent and is not a drug, nor is it approved for any clinical or therapeutic use. It is a polyethylene glycol (PEG) derivative containing an amino group and a terminal carboxylic acid. It is a water-soluble molecule that has a variety of applications in medical, environmental, and industrial research. The amino group is reactive with carboxylic acids, activated NHS esters, and carbonyls. The hydrophilic PEG spacer increases solubility in aqueous media. It is a valuable tool for medicinal chemists and chemical biologists working on targeted protein degradation and bioconjugation.
|
| Molecular Formula |
C10H21NO6
|
|---|---|
| Molecular Weight |
251.277
|
| Exact Mass |
251.137
|
| CAS # |
195071-49-9
|
| PubChem CID |
18508832
|
| Appearance |
Viscous Liquid
|
| LogP |
-4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
17
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NCCOCCOCCOCCOCC(O)=O
|
| InChi Key |
NPRAKTLKDKKZAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H21NO6/c11-1-2-14-3-4-15-5-6-16-7-8-17-9-10(12)13/h1-9,11H2,(H,12,13)
|
| Chemical Name |
2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~397.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9796 mL | 19.8981 mL | 39.7962 mL | |
| 5 mM | 0.7959 mL | 3.9796 mL | 7.9592 mL | |
| 10 mM | 0.3980 mL | 1.9898 mL | 3.9796 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
